In Vitro Activity of Cefiderocol Against European Multidrug-Resistant Enterobacterales: Implications for Resistance Modeling

Study Background and Research Question

Carbapenem-resistant Enterobacterales (CRE) are a growing threat in clinical microbiology, particularly as resistance rates rise across Europe and limit therapeutic options for serious infections. With the World Health Organization classifying CRE as critical priority pathogens, the need for robust, evidence-based insights into alternative and next-generation antibiotics becomes urgent. The reference study (Santerre Henriksen et al., 2024) addresses this gap by systematically evaluating the in vitro efficacy of cefiderocol against a large, geographically diverse panel of Enterobacterales collected from hospitalized patients in Europe, including strains resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations. The central research objective is to determine cefiderocol's performance relative to other existing and developmental agents, particularly in the context of resistance mechanisms prevalent in clinical isolates.

Key Innovation from the Reference Study

This investigation stands out due to its scale, rigor, and clinical relevance. The authors collected 1,909 clinical Enterobacterales isolates—including high proportions of Klebsiella spp., Escherichia coli, and Enterobacter spp.—across 49 sites in six European countries over a full calendar year. Unlike prior studies with limited isolate diversity or insufficient resistance phenotyping, this work directly compares cefiderocol's in vitro activity to both approved and developmental β-lactam/β-lactamase inhibitor regimens. Notably, meropenem resistance was defined using a high-dose MIC breakpoint, ensuring that the included strains represent practical, clinically relevant resistance. This enables robust, real-world insights into the utility of cefiderocol against multidrug-resistant pathogens.

Methods and Experimental Design Insights

The study utilized standardized antimicrobial susceptibility testing for all isolates, focusing on cefiderocol and a panel of β-lactam/β-lactamase inhibitor combinations, including both established (e.g., ceftazidime-avibactam, meropenem-vaborbactam) and developmental agents (e.g., cefepime-taniborbactam, aztreonam-avibactam). For meropenem-resistant and cefiderocol-resistant isolates, molecular analyses were performed: PCR was used to identify key β-lactamase genes, while whole-genome sequencing characterized resistance mechanisms in cefiderocol-resistant strains. This dual-level approach—phenotypic screening followed by genotypic investigation—enables the mapping of susceptibility patterns to underlying genetic mechanisms.

Importantly, bloodstream infections accounted for nearly half of all isolates, underscoring the clinical severity represented in the dataset. Susceptibility breakpoints were applied according to current clinical standards, and the study distinguishes between isolates resistant to meropenem, β-lactam/β-lactamase inhibitors, or both.

Core Findings and Why They Matter

Cefiderocol demonstrated high in vitro activity against Enterobacterales, including those resistant to meropenem and β-lactam/β-lactamase inhibitor combinations. Specifically, overall cefiderocol susceptibility was 98.1% across all Enterobacterales, compared to 78.1%–97.4% for approved β-lactam/β-lactamase inhibitors and 98.7%–99.1% for developmental agents (Santerre Henriksen et al., 2024). Among meropenem-resistant isolates, cefiderocol maintained an 87.8% susceptibility rate, vastly outperforming approved comparators (0%–71.6%) and approaching the efficacy of developmental combinations (93.2%–98.6%).

• Cefiderocol's activity was largely preserved even in the presence of carbapenemase genes (notably Klebsiella pneumoniae carbapenemase), with susceptibility dropping primarily in isolates harboring NDM, AmpC, or certain oxacillinase variants.
• All cefiderocol-resistant isolates (n = 37) showed multilayered resistance mechanisms, including iron uptake mutations (critical for cefiderocol's siderophore pathway), at least one carbapenemase gene, and often ftsI mutations.
• These results reinforce the value of early, parallel susceptibility testing for cefiderocol in multidrug-resistant Gram-negative infection workups, especially where metallo-β-lactamases are involved and treatment options are otherwise limited.

Given the severity of bloodstream and central nervous system infections in these contexts, the findings provide a foundation for research workflows aiming to model, understand, and ultimately overcome multidrug resistance.

Comparison with Existing Internal Articles

Several internal resources provide complementary perspectives on research tools and modeling strategies involving Gram-negative resistance and central nervous system infection models. For instance:

• The article "Cefepime (BMY-28142): Optimizing CNS Infection Research Workflows" details how cefepime's robust penetration of the blood-brain barrier and broad-spectrum activity supports reliable modeling of multidrug-resistant CNS infections. While cefiderocol's siderophore-mediated entry and resistance profile are distinct, the shared need for agents with strong antimicrobial activity against Gram-negative bacteria is evident.
• "Cefepime (BMY-28142): Translational Leverage in CNS Infection Models" emphasizes cefepime's utility in translational workflows, especially for Enterobacter cloacae resistance studies. The current reference paper expands this context by mapping resistance mechanisms and susceptibility profiles across a broader array of Enterobacterales, offering a more comprehensive backdrop for experimental design.
• Both technical and review articles converge on the importance of using blood-brain barrier-crossing antibiotics, such as cefepime, for CNS infection research and resistance modeling—paralleling the reference study's focus on antimicrobial activity in challenging clinical scenarios.

In synthesis, the reference study's comprehensive data on resistance mechanisms and susceptibility supports and extends these internal discussions by providing an evidence-based framework for selecting and validating antimicrobial agents in both basic and translational research contexts.

Limitations and Transferability

While the study's breadth and depth provide a robust evidence base, certain limitations should be considered:

• In vitro susceptibility does not always predict in vivo efficacy, especially in complex infection sites such as the central nervous system, where pharmacokinetics and host factors are critical.
• The geographic sampling, though extensive, is limited to Europe; resistance mechanisms and susceptibility profiles may vary in other regions.
• The focus on meropenem and β-lactam/β-lactamase inhibitor resistance means that rare or emerging resistance mechanisms could be underrepresented.

Nevertheless, the study's findings are highly transferable to research workflows modeling antimicrobial activity against Gram-negative bacteria, especially where high-level resistance is a central concern.

Protocol Parameters

• Isolate selection: Include clinical Enterobacterales strains with characterized resistance genotypes for benchmarking new antimicrobials.
• Susceptibility testing: Apply current clinical breakpoints for agents under investigation, ensuring comparison across both approved and developmental compounds.
• Molecular analysis: Use PCR and, when needed, whole-genome sequencing to map resistance genes and mutations, especially for isolates with unexpected susceptibility profiles.
• Blood-brain barrier modeling: For CNS infection research, incorporate antibiotics with validated CNS penetration, such as cefepime or cefiderocol, and reference pharmacokinetic data to guide dosing in model systems.
• Resistance mechanism mapping: Prioritize identification of carbapenemase genes (KPC, NDM), AmpC, and iron uptake pathway mutations to inform interpretation of susceptibility results.

Research Support Resources

For researchers designing bacterial infection models or central nervous system infection research workflows, access to high-quality reagents is essential. Cefepime (BMY-28142) (SKU BA1013) from APExBIO offers a validated, broad-spectrum cephalosporin antibiotic that crosses the blood-brain barrier and demonstrates reliable antimicrobial activity against both Gram-positive and Gram-negative bacteria. Its stability, spectrum, and established use in neurotoxicity and resistance studies make it suitable for supporting experimental designs informed by the latest resistance data. As with any research antibiotic, appropriate dosing and handling are crucial, especially given the potential for neurotoxicity in CNS models.